Blog

Drew Pardoll on Advancements in Cancer Immunotherapy and Future Innovations in Treatment and Detection

NFCR/LinkedIn

Oct 26, 2024, 15:33

Drew Pardoll on Advancements in Cancer Immunotherapy and Future Innovations in Treatment and Detection

National Foundation for Cancer Research (NFCR) posted on LinkedIn:

“Continuing our recap series of the NFCR Global Summit and Award Ceremonies for Cancer Research and Entrepreneurship, today we’re highlighting our first keynote speaker, Drew Pardoll, Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine. Dr. Pardoll set the stage for a powerful day, followed by two impactful panels: New Approaches to Cancer Treatments and Early Detection and Cancer Prevention. Stay tuned as we continue to share insights and moments from an inspiring event dedicated to advancing cancer research. The full recap of the event is now live.

The event began with a keynote address from Drew Pardoll, (Johns Hopkins University Medical School), who discussed the transformative impact of checkpoint inhibitors on cancer immunotherapies. Dr. Pardoll addressed the urgent need for biomarkers to predict patient responses, improved clinical trials, and emphasized the need for better combination therapies to make immunotherapy more effective for a broader range of cancer patients.

Panel on New Approaches to Cancer Treatments
During this panel, moderated by Lisa Coussens, (Oregon Health and Science University) innovative ideas and emerging areas in cancer treatment were discussed, with a strong emphasis on the critical need for personalized approaches. The session helped create a clear action plan for advancing research and developing new treatment strategies.

Panel on Early Detection and Cancer Prevention
Carlos Doti of AstraZeneca, moderated this panel of key leaders to explore current unmet needs, emerging technologies, clinical and policy challenges of implementing cancer screening, and potential strategies that could significantly improve patient outcomes.”